Literature DB >> 8594283

Ovarian cancer and gangrene of the digits: case report and review of the literature.

S F Chow1, C H McKenna.   

Abstract

Digital ischemia has been reported with various types of cancer, especially gastrointestinal. It is more common in elderly women than in any other group, and the most common symptom is a gangrenous finger (or fingers). More than half of the patients have metastatic involvement. Once the primary disease has been treated, when feasible, the digital symptoms usually regress or disappear. The presence of digital ischemia without other rheumatologic stigmata or vascular predisposition in an elderly patient should raise clinical suspicion of a paraneoplastic phenomenon. Herein we describe a 65-year old woman with digital ischemia associated with ovarian cancer. The diagnosis was established by biopsy after extremely high levels of cancer antigen 125 were detected.

Entities:  

Mesh:

Year:  1996        PMID: 8594283     DOI: 10.4065/71.3.253

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  4 in total

1.  [Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].

Authors:  M J Behne; U Hauswirth; A Menz; N Brüllke; U Müllerleile; I Moll
Journal:  Hautarzt       Date:  2008-11       Impact factor: 0.751

2.  Paraneoplastic acral vascular syndrome.

Authors:  Philipp Jud; Reinhard B Raggam; Franz Hafner
Journal:  CMAJ       Date:  2020-11-16       Impact factor: 8.262

3.  Digital necrosis with squamous cell carcinoma of the tonsil.

Authors:  Vinod Warrier; Ali Ahmad; Yaqoub Alshatti; Ali Jafar
Journal:  Int Med Case Rep J       Date:  2016-06-27

4.  Digital ischemia associated with cancer: results from a cohort study.

Authors:  Maëlle Le Besnerais; Sébastien Miranda; Nicole Cailleux; Nicolas Girszyn; Isabelle Marie; Hervé Lévesque; Ygal Benhamou
Journal:  Medicine (Baltimore)       Date:  2014-08       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.